Ebola and Marburg vaccines for Africa: One step closer

The Lancet

Volumn 385, Issue 9977, 2015, Pages 1491-1493

  Sridhar, Saranya ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EBOLA VACCINE; GLYCOPROTEIN; MARBURGVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

AFRICA; ANTIBODY RESPONSE; ANTIBODY TITER; CELLULAR IMMUNITY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MARBURG HEMORRHAGIC FEVER; MARBURGVIRUS; MORTALITY; NATIONAL HEALTH ORGANIZATION; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; UGANDAN; VACCINATION; VIRUS PATHOGENESIS; VIRUS STRAIN; VIRUS TRANSMISSION; WEST AFRICAN; BLOOD; FEMALE; IMMUNOLOGY; MALE;

ANTIBODIES, VIRAL; EBOLA VACCINES; EBOLAVIRUS; FEMALE; HUMANS; MALE; MARBURGVIRUS; VACCINES, DNA; VIRAL FUSION PROTEINS;

EID: 84928417617     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62445-4     Document Type: Note

References (11)

1. WHO Ebola response roadmap - situation report http://www.who.int/csr/disease/ebola/situation-reports/en/?m=20141217 Dec 17, 2014 (accessed Dec 18, 2014).
2. P Ascenzi, A Bocedi, J Heptonstall et al. Ebolavirus and Marburgvirus: insight the Filoviridae family Mol Aspects Med 29 2008 151 185
3. NJ Sullivan, JE Martin, BS Graham, GJ Nabel Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule Nat Rev Microbiol 7 2009 393 400
4. UN Sarwar, P Costner, ME Enama et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial J Infect Dis 2014 10.1093/infdis/jiu511 published online Sept 14.
5. JE Martin, NJ Sullivan, ME Enama et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial Clin Vaccine Immunol 13 2006 1267 1277
6. R Kanapathipillai, AM Henao Restrepo, P Fast et al. Ebola vaccine - an urgent international priority N Engl J Med 371 2014 2249 2251
7. H Kibuuka, NM Berkowitz, M Millard et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial Lancet 2014 published online Dec 23. http://dx.doi.org/10.1016/S0140-6736(14)62385-0
8. JE Ledgerwood, AD DeZure, DA Stanley et al. Chimpanzee adenovirus vector Ebola vaccine - preliminary report N Engl J Med 2014 10.1056/NEJMoa1410863 published online Nov 26.
9. YG Hur, P Gorak-Stolinska, MK Lalor et al. Factors affecting immunogenicity of BCG in infants, a study in Malawi, The Gambia and the UK BMC Infect Dis 14 2014 184
10. GF Black, RE Weir, S Flyod et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies Lancet 359 2002 1393 1401
11. DA Stanley, AN Honko, C Asiedu et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebolavirus challenge Nat Med 20 2014 1126 1129